- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 241/12 - Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
Patent holdings for IPC class C07D 241/12
Total number of patents in this class: 512
10-year publication summary
|
47
|
34
|
54
|
39
|
43
|
38
|
40
|
26
|
23
|
20
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Semiconductor Energy Laboratory Co., Ltd. | 11834 |
11 |
| Bristol-myers Squibb Company | 4751 |
10 |
| Amgen Inc. | 4429 |
10 |
| Guangzhou Magpie Pharmaceuticals Co., Ltd. | 30 |
10 |
| Novaled GmbH | 486 |
8 |
| Merck Sharp & Dohme LLC | 3736 |
8 |
| Syngenta Crop Protection AG | 6710 |
7 |
| Abbvie Inc. | 1824 |
7 |
| Calico Life Sciences LLC | 111 |
7 |
| F. Hoffmann-La Roche AG | 7819 |
6 |
| Hoffmann-La Roche Inc. | 3796 |
6 |
| Massachusetts Institute of Technology | 10254 |
6 |
| The General Hospital Corporation | 4871 |
6 |
| Arcus Biosciences, Inc. | 165 |
6 |
| The Broad Institute, Inc. | 1979 |
6 |
| Nippon Soda Co., Ltd. | 882 |
6 |
| Novartis AG | 10251 |
5 |
| The Regents of the University of California | 20778 |
5 |
| Bayer Pharma AG | 1009 |
5 |
| R.J. Reynolds Tobacco Company | 501 |
5 |
| Other owners | 372 |